Holen Sie sich die Stockscreener-App
40.00
25.04%
8.01
Handel nachbörslich:
39.97
-0.03
-0.08%
Schlusskurs vom Vortag:
$31.99
Offen:
$32.84
24-Stunden-Volumen:
1.61M
Relative Volume:
3.10
Marktkapitalisierung:
$1.94B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-101.63M
KGV:
-16.55
EPS:
-2.4171
Netto-Cashflow:
$-84.60M
1W Leistung:
+21.32%
1M Leistung:
+24.19%
6M Leistung:
+159.74%
1J Leistung:
+259.07%
1-Tages-Spanne:
$32.30
$41.19
1-Wochen-Bereich:
$31.32
$41.19
52-Wochen-Spanne:
$5.485
$41.19
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
40.00 | 1.55B | 0 | -101.63M | -84.60M | -2.4171 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-13 | Eingeleitet | Jefferies | Buy |
| 2025-10-27 | Eingeleitet | Guggenheim | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-11 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-16 | Eingeleitet | TD Cowen | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Oruka Therapeutics stock hits 52-week high at 36.53 USD - Investing.com
Assessing Oruka Therapeutics (ORKA) Valuation As ORKA-001 Moves Into Long Term Psoriasis Trial - Sahm
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Oruka psoriasis drug targets twice-yearly dosing in Phase 2 trials - Stock Titan
Should Oruka’s Once-Yearly ORKA-001 Psoriasis Dosing Ambition Require Action From Oruka Therapeutics (ORKA) Investors? - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Published on: 2026-03-08 05:39:15 - baoquankhu1.vn
Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 17.2% in February - MarketBeat
Is Oruka Therapeutics Inc. forming bullish engulfing patternsJuly 2025 Rallies & Smart Allocation Stock Reports - mfd.ru
Oruka Therapeutics COO Sandler sells $167,821 in shares - Investing.com
Oruka Therapeutics Inc expected to post a loss of 63 cents a shareEarnings Preview - TradingView
Insider Sell: Laura Sandler Sells 5,000 Shares of Oruka Therapeu - GuruFocus
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen - Defense World
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A 62% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday - MarketBeat
Oruka Therapeutics stock hits 52-week high at 36.53 USD By Investing.com - Investing.com Australia
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week HighWhat's Next? - MarketBeat
Oruka Therapeutics: A Potential Future Psoriasis Play (NASDAQ:ORKA) - Seeking Alpha
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Acquires New Holdings in Oruka Therapeutics, Inc. $ORKA - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
RTW INVESTMENTS, LP Expands Stake in Oruka Therapeutics Inc - GuruFocus
How Oruka Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Summary & Stepwise Trade Signal Guides - mfd.ru
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 71.70% Potential Upside In Biotech Innovation - DirectorsTalk Interviews
Will Oruka Therapeutics Inc outperform tech stocksJuly 2025 Chart Watch & Low Risk Entry Point Guides - baoquankhu1.vn
Evaluating Oruka Therapeutics (ORKA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares - MarketBeat
Big Money Moves: Whats the beta of Uniti Group Inc stockGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Aug Summary: Is Oruka Therapeutics Incs ROE strong enoughJuly 2025 Retail & Expert Approved Momentum Ideas - baoquankhu1.vn
Assessing Oruka Therapeutics (ORKA) Valuation After Recent Trading Cooldown - simplywall.st
Published on: 2026-02-15 16:13:39 - mfd.ru
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Promising 70% Upside Potential In Biotech - DirectorsTalk Interviews
How cyclical is Oruka Therapeutics Inc.’s revenue streamJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - mfd.ru
Candriam S.C.A. Buys 250,296 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
Is Oruka Therapeutics Inc. stock a contrarian buyWeekly Earnings Recap & Weekly Market Pulse Updates - mfd.ru
Will Oruka Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Action & Accurate Buy Signal Alerts - mfd.ru
Oruka Therapeutics to Participate in Multiple Upcoming Conferences - The Manila Times
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 77% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Dow Update: What is Oruka Therapeutics Incs book value per share2025 Retail Activity & Verified Swing Trading Watchlists - baoquankhu1.vn
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 31.3% in January - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Oruka Therapeutics, Inc. (ORKA) Stock Report: Biotechnology Pioneer Poised for 57.87% Upside - DirectorsTalk Interviews
Portfolio Update: Is Global Blue Group Holding AG Equity Warrant stock a top performer YTDQuarterly Growth Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
How cyclical is Oruka Therapeutics Incs revenue streamWeekly Investment Recap & Safe Capital Growth Stock Tips - baoquankhu1.vn
How Early ORKA-002 Dosing Data At Oruka Therapeutics (ORKA) Has Changed Its Investment Story - simplywall.st
H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap DownHere's What Happened - MarketBeat
Market Outlook: Does Oruka Therapeutics Inc stock have upside surprise potential2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oruka Therapeutics Inc-Aktie (ORKA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sandler Laura Lee | Chief Operating Officer |
Mar 02 '26 |
Sale |
33.56 |
5,000 |
167,822 |
237,584 |
| Goncalves Joana | Chief Medical Officer |
Feb 17 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
41,018 |
| Goncalves Joana | Chief Medical Officer |
Feb 17 '26 |
Sale |
32.37 |
7,000 |
226,559 |
34,018 |
| Goncalves Joana | Chief Medical Officer |
Jan 15 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
8,518 |
| Goncalves Joana | Chief Medical Officer |
Jan 15 '26 |
Sale |
31.81 |
7,000 |
222,704 |
1,518 |
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Option Exercise |
7.80 |
5,000 |
39,000 |
218,084 |
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Sale |
28.52 |
13,000 |
370,795 |
205,084 |
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):